Armata Pharmaceuticals, Inc. announced that the last subject has completed the company's Phase 1b/2a 'SWARM-P.a.' clinical trial of its lead candidate, AP-PA02, in cystic fibrosis (CF) subjects with chronic pulmonary Pseudomonas aeruginosa infection. In March 2020, Armata announced that it had been awarded up to $5 million in a therapeutic development award from the CF Foundation to advance development of AP-PA02.

In October 2021, the Foundation subsequently made an equity investment of $3 million in Armata to further support this program. The SWARM-P.a. study is a Phase 1b/2a, multi-center, double-blind, randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and tolerability of inhaled AP-PA02 in subjects with cystic fibrosis and chronic pulmonary Pseudomonas aeruginosa infection. The study has been conducted in collaboration with the Cystic Fibrosis Therapeutics Development Network (TDN), the largest CF clinical trials network.

For more information about the trial: NCT04596319.